BTK and B-cell chronic lymphocytic leukemia: Reversible, non-covalent BTK-inhibitors, such as pirtobrutinib or nemtabrutinib for instance, successfully target CLL cells exhibiting a BTK-C481 mutation and show promising efficacy in the treatment of CLL patients that have developed clinical resistance to ibrutinib therapy (93, 94).